Cancer research turbocharged at the Australian Synchrotron


By LabOnline Staff
Friday, 31 March, 2017


Synch

Minister for Industry, Innovation and Science Arthur Sinodinos today unveiled the Australian Cancer Research Foundation (ACRF) Detector, a device akin to a turbocharged camera, which will fast-track cancer research at the Australian Synchrotron by harnessing light a million times brighter than the sun.

Currently, more than 60% of all the research conducted on the synchrotron’s Micro Crystallography (MX2) beamline is conducted by cancer researchers. The new detector will enable these researchers to gain more answers at a faster rate, taking images at a speed and accuracy currently not possible at any other Australian research facility.

“The ACRF Detector is a vital, core piece of equipment for cancer and medical research in Australia, and one that will be used by cancer researchers from all institutes, hospitals and universities,” said Professor Ian Brown, CEO of the ACRF, which provided a $2 million grant for the detector.

“It shows the three-dimensional structure of proteins, which do most of the work in cells, identifying opportunities to neutralise those involved in cancer and promoting those that may protect us from cancer.”

Australian Synchrotron Director Professor Andrew Peele added that the detector will more than double the facility’s capacity to collect data, leading to more targeted and effective treatments and, ultimately, improved patient outcomes.

“This new capability will take a beamline that was previously at full capacity — booked for use at all available hours of the day — and find it an extra gear, so it can deliver more research, and arm researchers with clear representations of protein structures,” said Professor Peele.

“We’re essentially shifting from dial-up internet to high-speed broadband, putting our foot on the accelerator of cancer research technology, providing faster protein analysis to turbocharge cancer research and facilitate significant discoveries.”

Image caption: A depiction of anticancer drug Venclexta (blue) bound to its cancer target (orange). Images like this are generated from the MX2 beamline, which enables researchers to understand protein structures and then refine drug targets and drugs themselves. The new detector will turbocharge this and enable many more images to be captured, meaning more cancer and health research can be undertaken. Image credit: WEHI.

Related News

Perth clinical research company using electronic trial data capture

Perth-based research company Linear Clinical Research is using cloud-based technology to record...

RACI 2017 — chemophobia and green chemistry

It's a sad era for chemistry when you can buy chemical-free water, in a chemical-free plastic...

Lightweight X-ray machine approved by FDA

Adelaide-based start-up Micro-X has announced that its DRX Revolution Nano, a lightweight X-ray...


  • All content Copyright © 2017 Westwick-Farrow Pty Ltd